Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 21, 2022
Deals
Biogen’s acquisition conundrum
How Biogen could acquire its way into being a near-term growth company
BioCentury | May 4, 2022
Product Development
Biogen plots pipeline strategy as CEO readies to depart
Interim head of R&D says the biotech plans to stay the course in neuroscience, at least for now
BioCentury | Nov 20, 2021
Product Development
Is it time for Biogen to re-diversify?
Sandrock’s departure creates opportunity for his successor to reconsider neurology focus
BioCentury | Jun 19, 2020
Deals
In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program
BioCentury | Sep 18, 2019
Distillery Therapeutics
Preventing glial cell graft rejection with a T cell-targeting immunotherapy
BioCentury | Jul 23, 2019
Company News
Biogen prioritizing new areas as it awaits SMA landscape changes
BioCentury | Jan 26, 2019
Product Development
Target wide, test narrow in lupus
How the lupus field can springboard from its seven late-stage misses in 2018
BioCentury | Oct 26, 2018
Clinical News
Biogen, UCB report Phase IIb miss for lupus candidate dapirolizumab
Items per page:
1 - 10 of 11